Chikara Οhyama

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

Padmanee Sharma, Margitta Retz, Arlene O. Siefker‐Radtke et al. · The Lancet Oncology · 2017 · 1.7K citations

Urology, Metastatic Urothelial Carcinoma, Genitourinary Cancer +6

Influence of CYP3A5 and MDR1 (ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients

Norihiko Tsuchiya, Shigeru Satoh, Hitoshi Tada et al. · Transplantation · 2004 · 251 citations

Nrf2- and ATF4-Dependent Upregulation of xCT Modulates the Sensitivity of T24 Bladder Carcinoma Cells to Proteasome Inhibition

Ye Peng, Junsei Mimura, Tomomi Okada et al. · Molecular and Cellular Biology · 2014 · 197 citations · Full text

Cancer Research, Proteasome Inhibition, Urology +15

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N. et al. · The Lancet · 2017 · 175 citations · Full text

Platinum-based Therapy, Urology, Metastatic Urothelial Carcinoma +8

A mammalian homolog of the zebrafish transmembrane protein 2 (TMEM2) is the long-sought-after cell-surface hyaluronidase

Hayato Yamamoto, Yuki Tobisawa, Toshihiro Inubushi et al. · Journal of Biological Chemistry · 2017 · 161 citations · Full text